Wynants et al., 2017 - Google Patents
Clinical utility of risk models to refer patients with adnexal masses to specialized oncology care: multicenter external validation using decision curve analysisWynants et al., 2017
View PDF- Document ID
- 6846175769073884130
- Author
- Wynants L
- Timmerman D
- Verbakel J
- Testa A
- Savelli L
- Fischerova D
- Franchi D
- Van Holsbeke C
- Epstein E
- Froyman W
- Guerriero S
- Rossi A
- Fruscio R
- Leone F
- Bourne T
- Valentin L
- Van Calster B
- Publication year
- Publication venue
- Clinical Cancer Research
External Links
Snippet
Purpose: To evaluate the utility of preoperative diagnostic models for ovarian cancer based on ultrasound and/or biomarkers for referring patients to specialized oncology care. The investigated models were RMI, ROMA, and 3 models from the International Ovarian Tumor …
- 206010058897 Adnexa uteri mass 0 title abstract description 36
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/34—Computer-assisted medical diagnosis or treatment, e.g. computerised prescription or delivery of medication or diets, computerised local control of medical devices, medical expert systems or telemedicine
- G06F19/345—Medical expert systems, neural networks or other automated diagnosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wynants et al. | Clinical utility of risk models to refer patients with adnexal masses to specialized oncology care: multicenter external validation using decision curve analysis | |
| Timmerman et al. | Predicting the risk of malignancy in adnexal masses based on the Simple Rules from the International Ovarian Tumor Analysis group | |
| Meys et al. | Estimating risk of malignancy in adnexal masses: external validation of the ADNEX model and comparison with other frequently used ultrasound methods | |
| Van Holsbeke et al. | External validation of diagnostic models to estimate the risk of malignancy in adnexal masses | |
| Meng et al. | Diagnostic and prognostic value of carcinoembryonic antigen in pancreatic cancer: A systematic review and meta-analysis | |
| Sayasneh et al. | Evaluating the risk of ovarian cancer before surgery using the ADNEX model: a multicentre external validation study | |
| Shah et al. | Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125 | |
| Kaijser et al. | Improving strategies for diagnosing ovarian cancer: a summary of the International Ovarian Tumor Analysis (IOTA) studies | |
| Giannella et al. | A risk‐scoring model for the prediction of endometrial cancer among symptomatic postmenopausal women with endometrial thickness> 4 mm | |
| Burbos et al. | Predicting the risk of endometrial cancer in postmenopausal women presenting with vaginal bleeding: the Norwich DEFAB risk assessment tool | |
| Angioli et al. | A critical review on HE4 performance in endometrial cancer: where are we now? | |
| Van Calster et al. | Triaging women with ovarian masses for surgery: observational diagnostic study to compare RCOG guidelines with an International Ovarian Tumour Analysis (IOTA) group protocol | |
| Ionescu et al. | Correlation of ultrasound features and the Risk of Ovarian Malignancy Algorithm score for different histopathological subtypes of benign adnexal masses | |
| Auekitrungrueng et al. | Comparison of the diagnostic accuracy of International Ovarian Tumor Analysis simple rules and the risk of malignancy index to discriminate between benign and malignant adnexal masses | |
| Goff et al. | Combining a symptom index, CA125 and HE4 (triple screen) to detect ovarian cancer in women with a pelvic mass | |
| Bogani et al. | Predictors and patterns of local, regional, and distant failure in squamous cell carcinoma of the vulva | |
| Patel et al. | Endometrial thickness as measured by transvaginal ultrasound and the corresponding histopathologic diagnosis in women with postmenopausal bleeding | |
| Price et al. | CA 125 may not reflect disease status in patients with uterine serous carcinoma | |
| Piovano et al. | Diagnostic accuracy and cost‐effectiveness of different strategies to triage women with adnexal masses: a prospective study | |
| Suh-Burgmann et al. | Prospective validation of a standardized ultrasonography-based ovarian cancer risk assessment system | |
| Weber et al. | Risk factors for endometrial hyperplasia and cancer among women with abnormal bleeding | |
| Angioli et al. | REM (risk of endometrial malignancy): a proposal for a new scoring system to evaluate risk of endometrial malignancy | |
| Stukan et al. | Usefulness of diagnostic indices comprising clinical, sonographic, and biomarker data for discriminating benign from malignant ovarian masses | |
| Hashiguchi et al. | Prognostic significance of the number of lymph nodes examined in colon cancer surgery: clinical application beyond simple measurement | |
| Goodrich et al. | The effect of ovarian imaging on the clinical interpretation of a multivariate index assay |